News | April 19, 2025
Aptar commences clinical study to accelerate FDA approval of SmartTrack
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
Subscribe To Our Newsletter & Stay Updated
